Global Advanced Drug Delivery Systems Market Size study & Forecast, by Type ( Oral Drug Delivery System, Injection-based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Trans mucosal Drug Delivery System,

Global Advanced Drug Delivery Systems Market Size study & Forecast, by Type ( Oral Drug Delivery System, Injection-based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Trans mucosal Drug Delivery System, Carrier-based Drug Delivery System and Other Types) by Application ( Cardiovascular Diseases, Oncology, Urology, Diabetes, Central Nervous System, Ophthalmology and Others), by Technology ( Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery and Other Technologies) and Regional Analysis, 2023-2030

Global Advanced Drug Delivery Systems Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Advanced drug delivery systems (DDS) are technologies designed to optimize the delivery of drugs to their intended site of action in the body. These systems can enhance the efficacy, safety, and convenience of drug therapy by controlling the release, targeting, and localization of the drug. Advanced drug delivery systems offer numerous benefits over traditional drug delivery methods, including improved drug efficacy, reduced side effects, increased patient compliance, and enhanced convenience. They are also being actively researched for their potential to treat a wide range of diseases, including cancer, cardiovascular disease, and neurological disorders. The Advanced Drug Delivery Systems Market is expanding because of factors such as rising diabetes prevalence and prevalence of other diseases, the Development of new drugs and biologics and advancements in understanding human biology and diseases.

The rising prevalence of chronic diseases and cardiac vascular diseases is catering the market growth. according to a 2021 report from the International Diabetes Federation, India had an estimated 74,194.7 thousand cases of diabetes in 2021, and by 2030, that number is predicted to rise to 92,973.7 thousand cases. Furthermore, according to Robert Wood Johnson Foundation, in the year 2020, the incidences of chronic illness in the United States stood at 157 million cases which is projected to increase and reach 171 million cases by the year 2030. Furthermore, Self-injecting devices are becoming increasingly popular, and a significant class of medical devices has also recently arisen from the pipeline of biologics, biosimilars, and auto-injectors. A lot of businesses are concentrating on the introduction of fresh products that will support market expansion. For instance, Agile Therapeutics, Inc. commercially introduce Twirla (levonorgestrel and ethinyl estradiol) transdermal device in the United States in December 2020. Twirla is a new non-daily, non-invasive contraceptive patch. Additionally, in February 2022, Shin-Ya Biotechnology Co., Ltd., a Taiwanese medical wholesaler, placed an order for Nu Gen Medical Devices Inc.'s InsuJet needleless injection system. This is a component of a multi-year sales and distribution deal with an initial minimum commitment of USD 100,000 CDN and subsequent commitments for the following three years. In addition, advancements in Formulation and increased R&D Spending are creating lucrative growth in the market. However, the high cost of Advanced Drug Delivery Systems stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Advanced Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. According to the CDC, there will be roughly 37.3 million diabetics in the United States in 2020, including 28.7 million diagnosed and 8.5 million undiagnosed cases. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of diseases, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Becton, Dickinson and Company
Abbott Laboratories
Bayer AG
Boston Scientific Corporation
Kindeva Drug Delivery L.P.
Johnson & Johnson Pvt Ltd
Pfizer Inc.
Novartis AG
Medtronic
Ypsomed

Recent Developments in the Market:
 In March 2022, The FDA has given approval for Corium, Inc.'s ADLARITY (donepezil transdermal system) as a medication for people with Alzheimer's-related dementia who have mild, moderate, or severe symptoms. The only once-weekly patch that constantly and consistently administers doses of donepezil through the skin is ADLARITY.
 In March 2022, The US Food and Drug Administration has authorised the first generic form of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary illnesses: COPD, which includes chronic bronchitis and/or emphysema, and asthma in patients six years of age and older.

Global Advanced Drug Delivery Systems Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered -, Type, Application, Technology, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Oral Drug Delivery System
Injection-based Drug Delivery System
Inhalation/Pulmonary Drug Delivery System
Transdermal Drug Delivery System
Trans mucosal Drug Delivery System
Carrier-based Drug Delivery System
Other Types

By Application:
Cardiovascular Diseases
Oncology
Urology
Diabetes
Central Nervous System
Ophthalmology
Others

By Technology:
Prodrug
Implants and Intrauterine Devices
Targeted Drug Delivery
Polymeric Drug Delivery
Other Technologies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Becton, Dickinson and Company
Abbott Laboratories
Bayer AG
Boston Scientific Corporation
Kindeva Drug Delivery L.P.
Johnson & Johnson Pvt Ltd
Pfizer Inc.
Novartis AG
Medtronic
Ypsomed

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.